UK markets close in 5 hours 37 minutes

Karyopharm Therapeutics Inc. (KPTI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0500-0.0400 (-3.67%)
At close: 04:00PM EDT
1.0500 0.00 (0.00%)
After hours: 06:41PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 123.60M
Enterprise value 151.45M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.86
Price/book (mrq)N/A
Enterprise value/revenue 1.08
Enterprise value/EBITDA -1.85

Trading information

Stock price history

Beta (5Y monthly) 0.15
52-week change 3-52.70%
S&P500 52-week change 326.14%
52-week high 32.4700
52-week low 30.6170
50-day moving average 31.2260
200-day moving average 31.1218

Share statistics

Avg vol (3-month) 31.26M
Avg vol (10-day) 31.33M
Shares outstanding 5117.71M
Implied shares outstanding 6117.71M
Float 8107.82M
% held by insiders 110.20%
% held by institutions 166.89%
Shares short (15 May 2024) 417.56M
Short ratio (15 May 2024) 413.47
Short % of float (15 May 2024) 415.23%
Short % of shares outstanding (15 May 2024) 414.92%
Shares short (prior month 15 Apr 2024) 423.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -104.18%
Operating margin (ttm)-101.91%

Management effectiveness

Return on assets (ttm)-31.21%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)140.46M
Revenue per share (ttm)1.22
Quarterly revenue growth (yoy)-14.40%
Gross profit (ttm)N/A
EBITDA -132.07M
Net income avi to common (ttm)-146.34M
Diluted EPS (ttm)-1.2700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)148.58M
Total cash per share (mrq)1.26
Total debt (mrq)308.92M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.04
Book value per share (mrq)-1.45

Cash flow statement

Operating cash flow (ttm)-117.54M
Levered free cash flow (ttm)-63.77M